RT Journal Article
SR Electronic
T1 Depicting the regulatory role of JZOL on TRP channels in the treatment of Acute Bronchitis based on the combination of clinical trials, computational analysis and in vivo experiments
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.07.24306993
DO 10.1101/2024.05.07.24306993
A1 Fan, Qinhua
A1 Wu, Chongming
A1 Du, Yawei
A1 Wang, Boyang
A1 Xie, Yanming
A1 Zhang, Zeling
A1 Su, Wenquan
A1 Wang, Zizhuo
A1 Xu, Changchang
A1 Li, Xueke
A1 Ding, Ying
A1 An, Xinjiang
A1 Chen, Jing
A1 Xiao, Yunying
A1 Yu, Rong
A1 Li, Nan
A1 Wang, Juan
A1 Teng, Yiqun
A1 Lv, Hongfen
A1 Yang, Nian
A1 Wen, Yuling
A1 Huang, Xiaoli
A1 Pan, Wei
A1 Liu, Yufeng
A1 Xi, Xueqin
A1 Zhao, Qianye
A1 Liu, Changshan
A1 Xu, Jian
A1 Zhang, Haitao
A1 Zhuo, Lie
A1 Rong, Qiangquan
A1 Xia, Yu
A1 Shen, Qin
A1 Li, Shao
A1 Wang, Junhong
A1 Wu, Shengxian
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.05.07.24306993.abstract
AB The comparison between traditional Chinese medicine Jinzhen Oral Liquid (JZOL) and western medicine in treating children with acute bronchitis (AB) showed encouraging outcomes. This trial evaluated the efficacy and safety of the JZOL for improving cough and expectoration in children with AB. 480 children were randomly assigned to take JZOL or Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for 7 days. The primary outcome was time-to-cough resolution. The median time-to-cough resolution in both groups was 5.0 days and the antitussive onset median time was only 1 day. This head to head randomized controlled trial showed that JZOL was not inferior to cough suppressant and phlegm resolving western medicine in treating cough and sputum and could comprehensively treat respiratory and systemic discomfort symptoms. Combined with clinical trials, the mechanism of JZOL against AB was uncovered by network target analysis, it was found that the pathways in TRP channels like IL-1β/IL1R/TRPV1/TRPA1, NGF/TrkA/TRPV1/TRPA1 and PGE2/EP/PKA/TRPV1/TRPA1 might play important roles. Animal experiments further confirmed that inflammation and immune regulatory effect of JZOL in the treatment of AB were of vital importance and TRP channels was the key mechanism of action.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTrial registration: Chinese Clinical Trial Registry: ChiCTR2000034703Clinical Protocols https://www.chictr.org.cn/showproj.html?proj=56538 Funding StatementThis study was funded by the National Key Research and Development Program of the Ministry of Science and Technology of China in 2018, "Research on Modernization of TCM" project, "Demonstration Study on Evidence-based Evaluation and Effect mechanism of Ten Chinese patent Medicines and Classic famous prescriptions in the Treatment of Major Diseases after marketed" (2018YFC1707400 and 2018YFC17074101).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Dongzhimen Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data collected in this study are available to researchers through QinHua Fan (18810604390@163.com). Data requests will be reviewed and approved on the basis of scientific merit, and with a signed data access and sharing agreement. These data will be available for a minimum of 5 years after publication.ABacute bronchitisCAMComplementary and Alternative MedicineTCMTraditional Chinese medicineJZOLJinzhen Oral LiquidAHCHOSAmbroxol Hydrochloride and Clenbuterol Hydrochloride Oral SolutionAUCArea Under CurveHRhazard ratioITTintention-to-treatFASfull analysis setKEGGKyoto Encyclopedia of Genes and GenomesGOGene OntologyAEsadverse eventsADRsadverse drug reactionsThT-helperIFNinterferonTNFtumor necrosis factorLPSlipopolysaccharidePoly (I:C)polyinosinic acid-polycytidylic acidPPIpermeability indexBALFbronchoalveolar lavage fluidPGE2prostaglandin E2BKbradykinin.